Re My comment on Valuation of Cvac
Refer Prima Presentation Dated 27th Feb 2015 slide 40
Feb. 2014. Valeant (world’s No. 34 pharma company) acquired Provenge for 400 Million.
Provenge® 2014 US$304m net product revenue, up 7% -4Q14: Cash-flow break-even
Look at the figures Provane was / is a market leader and did great for a Yearly revenue of 304 Million at break-even so efficiency at production, distribution and marketing would make it profitable year 2 and so on.
So, given the newness of Cvac but with better results.. there is promise both in development and One off License sale
Re My comment on Valuation of Cvac Refer Prima Presentation...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.8¢ |
Change
-0.028(7.75%) |
Mkt cap ! $475.7M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 31.5¢ | $1.688M | 5.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 247596 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 341552 | 18 |
View Market Depth
| Last trade - 13.55pm 15/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |